Approximately 25–30% of patients with breast cancer belong to a subgroup who overexpress the ErbB2 (HER2) oncogene, and this is associated with a higher risk of disease progression and death (Meric et al, 2002). This evidence concerns the gene ERBB2 and breast carcinoma.